HRP20120286T1 - Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti - Google Patents
Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti Download PDFInfo
- Publication number
- HRP20120286T1 HRP20120286T1 HR20120286T HRP20120286T HRP20120286T1 HR P20120286 T1 HRP20120286 T1 HR P20120286T1 HR 20120286 T HR20120286 T HR 20120286T HR P20120286 T HRP20120286 T HR P20120286T HR P20120286 T1 HRP20120286 T1 HR P20120286T1
- Authority
- HR
- Croatia
- Prior art keywords
- physiologically acceptable
- combination
- acceptable salts
- glycopyrrolate
- pde
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title claims 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title claims 3
- 239000003112 inhibitor Substances 0.000 title claims 3
- 208000023504 respiratory system disease Diseases 0.000 title abstract 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 title 1
- 239000000812 cholinergic antagonist Substances 0.000 title 1
- 229940015042 glycopyrrolate Drugs 0.000 claims abstract 5
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960002586 roflumilast Drugs 0.000 claims abstract 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract 3
- 208000006673 asthma Diseases 0.000 claims abstract 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims 3
- 229950005741 rolipram Drugs 0.000 claims 3
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 230000001078 anti-cholinergic effect Effects 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 239000000168 bronchodilator agent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002636 symptomatic treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uporaba kombinacije topičkog R,R-glikopirolata ili njegove fiziološki prihvatljive soli s inhibitorima (PDE) 4 fosfodiesteraze odabrane iz skupine koja sadrži rolipram, roflumilast ili njihove fiziološki prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bronhijalne astme ili kronične opstruktivne bolesti pluća (COPD). Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Uporaba kombinacije topičkog R,R-glikopirolata ili njegove fiziološki prihvatljive soli s inhibitorima (PDE) 4 fosfodiesteraze odabrane iz skupine koja sadrži rolipram, roflumilast ili njihove fiziološki prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bronhijalne astme ili kronične opstruktivne bolesti pluća (COPD).
2. Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da je inhibitor (PDE) 4 fosfodiesteraze roflumilast ili njegove fiziološki prihvatljive soli.
3. Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da je inhibitor (PDE) 4 fosfodiesteraze rolipram ili njegove fiziološki prihvatljive soli.
4. Uporaba u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da je dnevna doza R,R-glikopirolata od 5 do 500 Pg, poželjno je od 15 do 300 Pg a dnevna doza PDE4 inhibitora između 200 i 5.000 Pg/dan, poželjno je 500 do 2.000 Pg/dan.
5. Uporaba u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time, da je dnevna doza R,R-glikopirolata od 5 do 100 Pg a dnevna doza PDE4 inhibitora između 200 i 5.000 Pg/dan, poželjno je 500 do 2.000 Pg/dan.
6. Postupak proizvodnje farmaceutskog pripravka za uporabu u liječenju bronhijalne astme ili kronične obstruktivne bolesti pluća COPD koji sadrži R,R-glikopirolat ili jedan od njegovih fiziološki prihvatljivih soli i najmanje inhibitor (PDE) 4 fosfodiesteraze odabranog iz skupine koja sadrži rolipram, roflumilast ili njihove fiziološki prihvatljiva soli, naznačen time, da su djelatne tvari predstavljene u fiksiranoj ili slobodnoj kombinaciji za istovremenu, uzastopnu ili odvojenu primjenu zajedno s uobičajenim ekscipijensima, dodacima i aditivima u farmaceutskom obliku prikladnom za primjenu putem inhalacije.
7. Postupak u skladu s patentnim zahtjevom 6, naznačen time, da su omogućene dvije djelatne tvari u prikladnoj veličini čestica za raspršivanje kada se inhaliraju.
8. Postupak u skladu s patentnim zahtjevom 6, naznačen time, da je aerosol za inhaliranje sa ili bez potisnog plina.
9. Postupak u skladu s patentnim zahtjevom 6, naznačen time, da je suhi prašak za inhalaciju.
10. Postupak u skladu s patentnim zahtjevom 6, naznačen time, da je suspenzija ili otopina za inhaliranje.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54195504P | 2004-02-06 | 2004-02-06 | |
| PCT/EP2005/000651 WO2005074982A2 (en) | 2004-02-06 | 2005-01-24 | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120286T1 true HRP20120286T1 (hr) | 2012-04-30 |
Family
ID=34837532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120286T HRP20120286T1 (hr) | 2004-02-06 | 2012-03-30 | Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20050175547A1 (hr) |
| EP (1) | EP1713471B1 (hr) |
| JP (1) | JP4700014B2 (hr) |
| CN (2) | CN100512813C (hr) |
| AT (1) | ATE541570T1 (hr) |
| AU (1) | AU2005210084B2 (hr) |
| CA (1) | CA2550848C (hr) |
| CY (1) | CY1112968T1 (hr) |
| DK (1) | DK1713471T3 (hr) |
| ES (1) | ES2381116T3 (hr) |
| HK (1) | HK1096311A1 (hr) |
| HR (1) | HRP20120286T1 (hr) |
| NO (1) | NO337023B1 (hr) |
| NZ (1) | NZ548301A (hr) |
| PL (1) | PL1713471T3 (hr) |
| PT (1) | PT1713471E (hr) |
| RU (1) | RU2437658C2 (hr) |
| SI (1) | SI1713471T1 (hr) |
| WO (1) | WO2005074982A2 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| JP2007524699A (ja) * | 2004-02-27 | 2007-08-30 | アルタナ ファルマ アクチエンゲゼルシャフト | ロフルミラストとグリコピロニウムとの組合せ物 |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| RU2008119323A (ru) * | 2005-10-19 | 2009-11-27 | Рэнбакси Лабораториз Лимитед (In) | Фармацевтические композиции мускаринового рецептора |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| WO2009052624A1 (en) * | 2007-10-25 | 2009-04-30 | Merck Frosst Canada Ltd. | Combination therapy |
| US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| GB2468073B (en) * | 2008-02-26 | 2012-09-05 | Elevation Pharmaceuticals Inc | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| JP6426624B2 (ja) * | 2013-01-28 | 2018-11-21 | インコゼン・セラピューティクス・プライベート・リミテッド | ロフルミラストｎ−酸化物の吸入によって自己免疫、呼吸器性および炎症性の障害を処置する方法 |
| EP2968313B1 (en) * | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| TW201542207A (zh) * | 2013-10-03 | 2015-11-16 | Otsuka Pharma Co Ltd | 嚴重氣喘治療劑 |
| CN104586841A (zh) * | 2013-10-30 | 2015-05-06 | 中国药科大学 | (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途 |
| CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
| RU2691110C2 (ru) * | 2017-11-20 | 2019-06-11 | Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) | Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ290266B6 (cs) * | 1993-07-02 | 2002-06-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
| WO1998000016A1 (en) * | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
| US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| AU7455498A (en) * | 1998-05-29 | 1999-12-20 | Citizen Watch Co. Ltd. | Method of subjecting ink jet printer to preuse treatment |
| EP1102579B1 (de) * | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| EP1862164A3 (de) * | 1998-11-13 | 2012-12-26 | Jagotec AG | Trockenpulver zur Inhalation |
| US6086914A (en) * | 1999-03-12 | 2000-07-11 | Weinstein; Robert E. | Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity |
| DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US20040002548A1 (en) * | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| US20040028958A1 (en) * | 2002-06-18 | 2004-02-12 | Total Innovative Manufacturing Llc | Recyclable fire-resistant moldable batt and panels formed therefrom |
| DE19961300A1 (de) * | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0029903D0 (en) * | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
| DE50211045D1 (de) | 2001-03-30 | 2007-11-22 | Jagotec Ag | Medizinische aerosolformulierungen |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| ATE347361T1 (de) * | 2001-05-25 | 2006-12-15 | Boehringer Ingelheim Pharma | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen |
| EP1395288A1 (en) * | 2001-05-25 | 2004-03-10 | Pfizer Inc. | A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
| GB0118373D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| US7258118B2 (en) * | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| US20040038958A1 (en) * | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
| UA82323C2 (uk) * | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
| US20040053902A1 (en) * | 2002-09-13 | 2004-03-18 | Smith C. Steven | Novel composition and method for treatment of upper respiratory conditions |
| CA2519682A1 (en) | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| CA2519679C (en) * | 2003-03-28 | 2012-08-28 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| JP2007530917A (ja) | 2003-07-11 | 2007-11-01 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 改善された周波数決定 |
-
2005
- 2005-01-24 CN CNB200580002345XA patent/CN100512813C/zh not_active Expired - Fee Related
- 2005-01-24 JP JP2006551762A patent/JP4700014B2/ja not_active Expired - Fee Related
- 2005-01-24 PL PL05701141T patent/PL1713471T3/pl unknown
- 2005-01-24 DK DK05701141.3T patent/DK1713471T3/da active
- 2005-01-24 RU RU2006132040/15A patent/RU2437658C2/ru not_active Application Discontinuation
- 2005-01-24 NZ NZ548301A patent/NZ548301A/en unknown
- 2005-01-24 CN CN200910133531A patent/CN101518532A/zh active Pending
- 2005-01-24 SI SI200531513T patent/SI1713471T1/sl unknown
- 2005-01-24 CA CA2550848A patent/CA2550848C/en not_active Expired - Fee Related
- 2005-01-24 AT AT05701141T patent/ATE541570T1/de active
- 2005-01-24 WO PCT/EP2005/000651 patent/WO2005074982A2/en active Application Filing
- 2005-01-24 ES ES05701141T patent/ES2381116T3/es active Active
- 2005-01-24 EP EP05701141A patent/EP1713471B1/en active Active
- 2005-01-24 PT PT05701141T patent/PT1713471E/pt unknown
- 2005-01-24 AU AU2005210084A patent/AU2005210084B2/en not_active Ceased
- 2005-02-07 US US11/051,463 patent/US20050175547A1/en not_active Abandoned
-
2006
- 2006-07-13 US US11/485,486 patent/US20060251589A1/en not_active Abandoned
- 2006-08-31 NO NO20063880A patent/NO337023B1/no not_active IP Right Cessation
-
2007
- 2007-04-11 HK HK07103735.7A patent/HK1096311A1/xx not_active IP Right Cessation
-
2009
- 2009-02-03 US US12/365,003 patent/US8097605B2/en active Active
-
2012
- 2012-03-29 CY CY20121100323T patent/CY1112968T1/el unknown
- 2012-03-30 HR HR20120286T patent/HRP20120286T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1713471T3 (pl) | 2012-06-29 |
| ES2381116T3 (es) | 2012-05-23 |
| CA2550848C (en) | 2013-02-26 |
| DK1713471T3 (da) | 2012-05-14 |
| AU2005210084A1 (en) | 2005-08-18 |
| SI1713471T1 (sl) | 2012-07-31 |
| US8097605B2 (en) | 2012-01-17 |
| JP2007520507A (ja) | 2007-07-26 |
| NO20063880L (no) | 2006-11-02 |
| CA2550848A1 (en) | 2005-08-18 |
| RU2437658C2 (ru) | 2011-12-27 |
| JP4700014B2 (ja) | 2011-06-15 |
| US20060251589A1 (en) | 2006-11-09 |
| ATE541570T1 (de) | 2012-02-15 |
| CY1112968T1 (el) | 2016-04-13 |
| WO2005074982A3 (en) | 2006-04-06 |
| HK1096311A1 (en) | 2007-06-01 |
| CN100512813C (zh) | 2009-07-15 |
| CN1909899A (zh) | 2007-02-07 |
| RU2006132040A (ru) | 2008-03-20 |
| US20050175547A1 (en) | 2005-08-11 |
| US20090136429A1 (en) | 2009-05-28 |
| AU2005210084B2 (en) | 2010-06-24 |
| NZ548301A (en) | 2010-07-30 |
| CN101518532A (zh) | 2009-09-02 |
| PT1713471E (pt) | 2012-04-10 |
| EP1713471A2 (en) | 2006-10-25 |
| WO2005074982A2 (en) | 2005-08-18 |
| EP1713471B1 (en) | 2012-01-18 |
| NO337023B1 (no) | 2015-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120286T1 (hr) | Kombinacija antikolinergika i inhibitora fosfodiesteraze tip 4 za liječenje respiratornih bolesti | |
| HRP20160373T1 (hr) | Kombinacija antikolinergika i antagonista leukotrien receptora za liječenje bolesti dišnog sustava | |
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| AU2005240404B2 (en) | Treating respiratory diseases with gycopyrrolate and analogues | |
| AU2001295760A1 (en) | Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders | |
| CN101389313A (zh) | 用于吸入疗法的雾化抗生素 | |
| CA2550841A1 (en) | Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases | |
| HRP20130052T1 (hr) | Lijeäśenje respiratorne bolesti | |
| JP2018536014A (ja) | 液体ニコチン製剤 | |
| WO2007123955A3 (en) | Stable hydroalcoholic oral spray formulations and methods | |
| JP2007520507A5 (hr) | ||
| ES2303645T3 (es) | Composiciones para prevenir y tratar sintomas de tipo resfriado y gripe que comprenden cinc quelado. | |
| HRP20140707T1 (hr) | KOMBINACIJA ATORVASTATINA ILI SIMVASTATINA KAO INHIBITORA REDUKTAZE HMG-CoA S INHIBITOROM FOSFODIESTERAZE 4 KOJI JE ROFLUMILAST, ZA LIJEČENJE UPALNIH BOLESTI PLUĆA | |
| KR20070042917A (ko) | 소아 천식의 치료 | |
| DE60216588D1 (de) | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen | |
| JP2012503668A5 (hr) | ||
| HRP20220929T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje astme | |
| JP2008533072A5 (hr) | ||
| NZ593695A (en) | Alkaloid aminoester derivatives and medicinal composition thereof | |
| JP2015519356A5 (hr) | ||
| HRP20050579A2 (hr) | Nove sinergistične kombinacije koje sadrže roflumilast i formoterol | |
| EP1583559B1 (en) | Compositions for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers | |
| MEP54308A (hr) | Aerosolna formulacija za inhaliranje koja sadrži triotropijumovu so | |
| WO2010146394A1 (en) | Theobromine for the treatment of cough | |
| PL211574B1 (pl) | Kompozycja farmaceutyczna zawierająca mieszankę pierwszego aktywnego składnika wybranego grupy składającej się z roflumilastu jego farmaceutycznie akceptowanych soli i N-tlenków;i drugiego aktywnego składnika wybranego z grupy składającej się z cetyryzyny i jej farmaceutycznie akceptowanych soli, zastosowanie wspomnianej kompozycji, sposób wytwarzania wspomnianej kompozycji, produkt farmaceutyczny zawierający preparaty wspomnianych składników aktywnych oraz zastosowanie wspomnianego produktu farmaceutycznego |